Skip to main content
. 2022 Jun 21;10(7):984. doi: 10.3390/vaccines10070984

Figure 1.

Figure 1

Characterization of immune protection by COVID-19 vaccines. Data obtained in Moscow for the summer of 2021. (a) The estimated effectiveness values of the Sputnik V and EpiVacCorona vaccines in preventing severe forms of COVID-19. The analysis is based on data from July 2021. The upper chart shows the results of the analysis performed with a control group of unvaccinated Moscow residents, and the lower chart corresponds to the data analysis performed with a control group of seronegative individuals. The VE estimates for the Sputnik V vaccine were positive and highly significant (p < 0.001) by the chi-square test for both age groups. The VE values for EpiVacCorona vaccines were negative and nonsignificant (p > 0.05) for the 18–50 age group and negative and significant for the 50+ age group (p < 0.001). (b) The panel shows the number of deaths and severe cases of COVID-19 among fully vaccinated or seronegative Moscow residents, normalized per 10,000 person-years.